Noah A Levit

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 13

Top Topics

Atopic Dermatitis

Top Venues

Paediatric drugs

American journal of clinical dermatology

Dermatology and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Jonathan Ian Silverberg, Charles W Lynde, Katrina Abuabara, Cataldo Patruno, Anna De Benedetto, Haixin Zhang, Ryan B Thomas, Gaëlle Bégo-Le-Bagousse, Faisal A Khokhar, Jignesh Vakil, Ainara Rodríguez Marco, Noah A Levit
Publisher Correction to: Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials. American journal of clinical dermatology (2023)
Michael J Cork, Diamant Thaçi, Lawrence F Eichenfield, Peter D Arkwright, Zhen Chen, Ryan B Thomas, Matthew P Kosloski, Ariane Dubost-Brama, Randy Prescilla, Ashish Bansal, Noah A Levit
Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic Dermatitis. Dermatology and therapy (2023)
Jonathan Ian Silverberg, Charles W Lynde, Katrina Abuabara, Cataldo Patruno, Anna De Benedetto, Haixin Zhang, Ryan B Thomas, Gaëlle Bégo-Le-Bagousse, Faisal A Khokhar, Jignesh Vakil, Ainara Rodríguez Marco, Noah A Levit
Publisher Correction to: Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials. American journal of clinical dermatology (2023)
Jonathan Ian Silverberg, Charles W Lynde, Katrina Abuabara, Cataldo Patruno, Anna De Benedetto, Haixin Zhang, Ryan B Thomas, Gaëlle Bégo-Le-Bagousse, Faisal A Khokhar, Jignesh Vakil, Ainara Rodríguez Marco, Noah A Levit
Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials. American journal of clinical dermatology (2023)
Amy S Paller, Elaine C Siegfried, Michael J Cork, Andreas Wollenberg, Peter D Arkwright, Mercedes E Gonzalez, Benjamin Lockshin, Zhen Chen, Ashish Bansal, Noah A Levit, Randy Prescilla
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis. Paediatric drugs (2022)
Amy S Paller, Elaine C Siegfried, Michael J Cork, Andreas Wollenberg, Peter D Arkwright, Mercedes E Gonzalez, Benjamin Lockshin, Zhen Chen, Ashish Bansal, Noah A Levit, Randy Prescilla
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis. Paediatric drugs 25 (1) (2022)
Amy S Paller, Elaine C Siegfried, Michael J Cork, Andreas Wollenberg, Peter D Arkwright, Mercedes E Gonzalez, Benjamin Lockshin, Zhen Chen, Ashish Bansal, Noah A Levit, Randy Prescilla
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis. Paediatric drugs 25 (1) (2022)
El-Bdaoui Haddad, Sonya L Cyr, Kazuhiko Arima, Robert A McDonald, Noah A Levit, Frank O Nestle
Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis. Dermatology and therapy 12 (7) (2022)
Amy S Paller, Elaine C Siegfried, Michael J Cork, Andreas Wollenberg, Peter D Arkwright, Mercedes E Gonzalez, Benjamin Lockshin, Zhen Chen, Ashish Bansal, Noah A Levit, Randy Prescilla
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis. Paediatric drugs 25 (1) (2022)
Amy S Paller, Elaine C Siegfried, Michael J Cork, Andreas Wollenberg, Peter D Arkwright, Mercedes E Gonzalez, Benjamin Lockshin, Zhen Chen, Ashish Bansal, Noah A Levit, Randy Prescilla
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis. Paediatric drugs 25 (1) (2022)
Amy S Paller, Elaine C Siegfried, Michael J Cork, Andreas Wollenberg, Peter D Arkwright, Mercedes E Gonzalez, Benjamin Lockshin, Zhen Chen, Ashish Bansal, Noah A Levit, Randy Prescilla
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis. Paediatric drugs 25 (1) (2022)
Evgeny V Berdyshev, Elena Goleva, Robert Bissonnette, Irina Bronova, Anna Sofia Bronoff, Brittany N Richers, Shannon Garcia, Marco Ramirez-Gama, Patricia Taylor, Amy Praestgaard, Inoncent Agueusop, Pauline Jurvilliers, Mark Boguniewicz, Noah A Levit, Ana Beatris Rossi, Annie Zhang, Donald Y M Leung
Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis. Allergy 77 (11) (2022)
Amy S Paller, Andreas Wollenberg, Elaine Siegfried, Diamant Thaçi, Michael J Cork, Peter D Arkwright, Melinda Gooderham, Xian Sun, John T O'Malley, Faisal A Khokhar, Jignesh Vakil, Ashish Bansal, Karli Rosner, Brad Shumel, Noah A Levit
Laboratory Safety of Dupilumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial. Paediatric drugs 23 (5) (2021)